Woo Y J, Raju G P, Swain J L, Richmond M E, Gardner T J, Balice-Gordon R J
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia 19104-6074, USA.
Circulation. 1997 Nov 18;96(10):3561-9. doi: 10.1161/01.cir.96.10.3561.
The relationship among the maternal, placental, and uniquely shunted embryonic circulation was explored to provide access to the embryonic cardiovascular system in utero. Manipulation of gene expression in the developing heart would be particularly useful for studying the effects of altered gene expression on cardiac development and in the etiology of congenital cardiac anomalies.
Dye studies demonstrated that intraplacental injection allows direct access to the embryonic cardiac and systemic circulation. To evaluate the efficacy of cardiac gene transfer using this approach, replication-deficient recombinant adenoviral vectors encoding luciferase or beta-galactosidase as reporter genes were injected intraplacentally into embryonic day (E)12.5 murine embryos, an age at which the mass of the heart was observed to be large compared with other organs. Embryos were assayed for transgene expression at E15.5 and at birth. Survival rates at these times were similar among vector-injected and control groups. At E15.5 and at birth, luciferase activity within the heart was 9- and 23-fold higher, respectively, than in the remainder of the embryo, although levels of expression were generally lower at birth than during embryonic life. Beta-galactosidase expression was observed within all regions of the embryonic heart and was localized to approximately 15% of atrial and ventricular cells.
Intraplacental delivery of adenovirus at embryonic day 12.5 results in somatic gene transfer to the murine embryonic heart, which persists at least until birth. The combination of intraplacental injection to directly access the fetal coronary circulation and injection at E12.5 when the mass of the heart is large compared with other organs results in transgene expression in cardiac cells. Intraplacental injections early in embryonic life may thus be useful to study the effects of temporal manipulation of gene expression on cardiac development and disease.
研究母体、胎盘和独特分流的胚胎循环之间的关系,以便在子宫内进入胚胎心血管系统。操纵发育中心脏的基因表达对于研究基因表达改变对心脏发育的影响以及先天性心脏异常的病因学将特别有用。
染料研究表明,胎盘内注射可直接进入胚胎心脏和体循环。为了评估使用这种方法进行心脏基因转移的效果,将编码荧光素酶或β-半乳糖苷酶作为报告基因的复制缺陷型重组腺病毒载体经胎盘注射到胚胎第(E)12.5天的小鼠胚胎中,这个年龄段的心脏质量相对于其他器官较大。在E15.5和出生时对胚胎进行转基因表达检测。载体注射组和对照组在这些时间的存活率相似。在E15.5和出生时,心脏内的荧光素酶活性分别比胚胎其余部分高9倍和23倍,尽管出生时的表达水平通常低于胚胎期。在胚胎心脏的所有区域均观察到β-半乳糖苷酶表达,且定位在约15%的心房和心室细胞中。
在胚胎第12.5天经胎盘递送腺病毒可导致向小鼠胚胎心脏进行体细胞基因转移,这种转移至少持续到出生。经胎盘注射直接进入胎儿冠状动脉循环,以及在心脏质量相对于其他器官较大的E12.5进行注射,可导致心脏细胞中的转基因表达。因此,胚胎早期经胎盘注射可能有助于研究基因表达的时间操纵对心脏发育和疾病 的影响。